Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Josamycin→

Josamycin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
16846-24-5
Molecular formula
C42H69NO15
Molecular weight
827.995 g/mol
Drug class
Macrolide antibacterial50S ribosomal subunit inhibitor
Mechanism of action
Binds the 50S bacterial ribosomal subunit and inhibits protein synthesis by interfering with peptide-chain elongation and translocation.
Indications / reported uses
  • Treatment of infections caused by josamycin-susceptible bacteria, including selected respiratory, skin/soft-tissue and atypical bacterial infections in countries where authorised; use should follow local susceptibility and antimicrobial guidance

Sources: NLM MeSH — Josamycin · PubMed — Josamycin clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Josamycin Environmental Risk Assessment (ERA) (the Josamycin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.